Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Immunic Inc's Business Segments
Immunic Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Reportable0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | - | - |
Description of Immunic Inc
Immunic Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for the treatment of various immune-mediated diseases. The company was founded in 2016 and is headquartered in New York, with additional offices in Munich, Germany.
The primary goal of Immunic is to develop small molecule drugs that modulate the immune system to target specific diseases. These diseases may include autoimmune disorders, chronic inflammation, and cancer. The company's approach is centered around the discovery and development of selective oral immunometabolic drugs.
Immunic has a diverse pipeline of drug candidates targeting different immune-mediated diseases. One of its lead drug candidates is IMU-838, which is being developed for the treatment of multiple sclerosis (MS), ulcerative colitis (UC), and Crohn's disease (CD). IMU-838 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine biosynthesis pathway. By inhibiting this pathway, IMU-838 has the potential to reduce inflammation and control the immune response.
Another drug candidate in Immunic's pipeline is IMU-935, which targets the treatment of Parkinson's disease. IMU-935 is a small molecule inhibitor of the enzyme monoacylglycerol lipase (MAGL), which is involved in the metabolism of endocannabinoids. By modulating the endocannabinoid system, IMU-935 aims to reduce neuroinflammation and protect dopaminergic neurons in Parkinson's disease.
In addition to its lead candidates, Immunic is also developing IMU-856, which is being explored for the treatment of primary sclerosing cholangitis (PSC), a rare autoimmune liver disease. IMU-856 is a selective antagonist of RORγt, a nuclear receptor specifically expressed in immune cells that play a critical role in autoimmune diseases.
The company applies a comprehensive approach to drug development, encompassing preclinical research, clinical trials, regulatory affairs, and commercialization strategies. Immunic's team consists of experienced scientists, clinicians, and industry professionals who collaborate to bring novel therapies to patients in need.
Immunic is also actively engaged in strategic partnerships and collaborations to accelerate drug development and enhance its capabilities. The company has collaborations with various academic institutions and has received funding from government grants and venture capital investments.
Overall, Immunic Inc is a biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases. With a robust pipeline and a dedicated team, the company aims to provide effective treatment options for patients suffering from autoimmune disorders and chronic inflammation.
The primary goal of Immunic is to develop small molecule drugs that modulate the immune system to target specific diseases. These diseases may include autoimmune disorders, chronic inflammation, and cancer. The company's approach is centered around the discovery and development of selective oral immunometabolic drugs.
Immunic has a diverse pipeline of drug candidates targeting different immune-mediated diseases. One of its lead drug candidates is IMU-838, which is being developed for the treatment of multiple sclerosis (MS), ulcerative colitis (UC), and Crohn's disease (CD). IMU-838 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the de novo pyrimidine biosynthesis pathway. By inhibiting this pathway, IMU-838 has the potential to reduce inflammation and control the immune response.
Another drug candidate in Immunic's pipeline is IMU-935, which targets the treatment of Parkinson's disease. IMU-935 is a small molecule inhibitor of the enzyme monoacylglycerol lipase (MAGL), which is involved in the metabolism of endocannabinoids. By modulating the endocannabinoid system, IMU-935 aims to reduce neuroinflammation and protect dopaminergic neurons in Parkinson's disease.
In addition to its lead candidates, Immunic is also developing IMU-856, which is being explored for the treatment of primary sclerosing cholangitis (PSC), a rare autoimmune liver disease. IMU-856 is a selective antagonist of RORγt, a nuclear receptor specifically expressed in immune cells that play a critical role in autoimmune diseases.
The company applies a comprehensive approach to drug development, encompassing preclinical research, clinical trials, regulatory affairs, and commercialization strategies. Immunic's team consists of experienced scientists, clinicians, and industry professionals who collaborate to bring novel therapies to patients in need.
Immunic is also actively engaged in strategic partnerships and collaborations to accelerate drug development and enhance its capabilities. The company has collaborations with various academic institutions and has received funding from government grants and venture capital investments.
Overall, Immunic Inc is a biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases. With a robust pipeline and a dedicated team, the company aims to provide effective treatment options for patients suffering from autoimmune disorders and chronic inflammation.
Immunic Inc. is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. the company has been engaged in the development of several products and services that target a range of conditions, primarily using its proprietary platform.
Segments
1. Research and Development
- Immunic invests heavily in R&D to explore novel therapeutic approaches. This segment typically encompasses discovering new drug candidates, preclinical testing, and advancing compounds into clinical trials. It utilizes cutting-edge technologies and methodologies to facilitate drug development.
2. Clinical Development
- This segment handles the clinical trials necessary for evaluating the safety and efficacy of new therapies. Immunic has ongoing and planned studies outside the traditional phases, including Phase I, II, and III trials focusing on various autoimmune diseases. The company actively engages in collaborative efforts with clinical research organizations (CROs) to conduct these studies.
3. Regulatory Affairs
- To bring products to market, Immunic navigates complex regulatory landscapes. This segment focuses on ensuring compliance with health authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). Regulatory submissions, data management, and adherence to good clinical practices (GCP) are key responsibilities in this segment.
4. Commercialization Strategy
- Once a product is approved, the commercialization segment is crucial for market launch strategies, including market access, pricing, distribution, and marketing efforts. Immunic’s approach often involves partnerships with other pharmaceutical companies for broader reach and distribution networks.
Products
Immunic Inc. has developed several promising therapeutic candidates:
1. IMU-838
- This oral small molecule inhibitor targets the activation of the immune system, specifically inhibiting the enzymes involved in inflammatory pathways. It is designed for treating conditions like multiple sclerosis (MS) and ulcerative colitis (UC). IMU-838 has undergone various clinical trials, showing potential in reducing disease activity and improving patient symptoms.
2. IMU-935
- Another oral therapy, IMU-935, operates by modulating the immune response in autoimmune diseases, particularly amid inflammatory and autoimmune conditions. It has been studied for effectiveness in conditions like psoriasis and other related skin disorders.
3. IMU-856
- This investigational product represents an innovative approach to treating inflammatory bowel disease (IBD) with a focus on restoring gut health and microbiome balance. Research in this area has garnered attention due to the increasing incidence of IBD globally.
Services
Immunic Inc. also offers a range of services that contribute to its overall mission:
1. Clinical Trial Management Services
- Immunic manages its own clinical trials and may provide services for external partners as well, including study design, recruitment strategies, and monitoring.
2. Biomarker Discovery Services
- The company invests in biomarker research to better predict treatment responses in patients and tailor therapies to individual needs. This service aids in the development of personalized medicine approaches.
3. Collaboration and Licensing Opportunities
- Immunic may provide opportunities for collaboration with other research entities, universities, and pharmaceutical companies to leverage their expertise, technologies, or compounds.
4. Consultative Services
- Offering strategic consulting for new drug developments, regulatory strategy, and market entry plans based on their extensive knowledge of the biotechnology landscape.
Conclusion
Overall, Immunic Inc. is positioned at the intersection of innovative drug development and strategic commercialization efforts, focusing on addressing unmet needs in the treatment of autoimmune and inflammatory disorders. The companys commitment to R&D and its robust pipeline of therapeutic candidates highlight its role in advancing healthcare solutions for complex medical challenges.
Segments
1. Research and Development
- Immunic invests heavily in R&D to explore novel therapeutic approaches. This segment typically encompasses discovering new drug candidates, preclinical testing, and advancing compounds into clinical trials. It utilizes cutting-edge technologies and methodologies to facilitate drug development.
2. Clinical Development
- This segment handles the clinical trials necessary for evaluating the safety and efficacy of new therapies. Immunic has ongoing and planned studies outside the traditional phases, including Phase I, II, and III trials focusing on various autoimmune diseases. The company actively engages in collaborative efforts with clinical research organizations (CROs) to conduct these studies.
3. Regulatory Affairs
- To bring products to market, Immunic navigates complex regulatory landscapes. This segment focuses on ensuring compliance with health authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency). Regulatory submissions, data management, and adherence to good clinical practices (GCP) are key responsibilities in this segment.
4. Commercialization Strategy
- Once a product is approved, the commercialization segment is crucial for market launch strategies, including market access, pricing, distribution, and marketing efforts. Immunic’s approach often involves partnerships with other pharmaceutical companies for broader reach and distribution networks.
Products
Immunic Inc. has developed several promising therapeutic candidates:
1. IMU-838
- This oral small molecule inhibitor targets the activation of the immune system, specifically inhibiting the enzymes involved in inflammatory pathways. It is designed for treating conditions like multiple sclerosis (MS) and ulcerative colitis (UC). IMU-838 has undergone various clinical trials, showing potential in reducing disease activity and improving patient symptoms.
2. IMU-935
- Another oral therapy, IMU-935, operates by modulating the immune response in autoimmune diseases, particularly amid inflammatory and autoimmune conditions. It has been studied for effectiveness in conditions like psoriasis and other related skin disorders.
3. IMU-856
- This investigational product represents an innovative approach to treating inflammatory bowel disease (IBD) with a focus on restoring gut health and microbiome balance. Research in this area has garnered attention due to the increasing incidence of IBD globally.
Services
Immunic Inc. also offers a range of services that contribute to its overall mission:
1. Clinical Trial Management Services
- Immunic manages its own clinical trials and may provide services for external partners as well, including study design, recruitment strategies, and monitoring.
2. Biomarker Discovery Services
- The company invests in biomarker research to better predict treatment responses in patients and tailor therapies to individual needs. This service aids in the development of personalized medicine approaches.
3. Collaboration and Licensing Opportunities
- Immunic may provide opportunities for collaboration with other research entities, universities, and pharmaceutical companies to leverage their expertise, technologies, or compounds.
4. Consultative Services
- Offering strategic consulting for new drug developments, regulatory strategy, and market entry plans based on their extensive knowledge of the biotechnology landscape.
Conclusion
Overall, Immunic Inc. is positioned at the intersection of innovative drug development and strategic commercialization efforts, focusing on addressing unmet needs in the treatment of autoimmune and inflammatory disorders. The companys commitment to R&D and its robust pipeline of therapeutic candidates highlight its role in advancing healthcare solutions for complex medical challenges.